John Bertin

机构：GlaxoSmithKline (United States) · ORCID：0000-0001-9048-1650

发表论文 199 篇 · 总被引 33131 次 · h-index 82

代表论文

• Pathogen blockade of TAK1 triggers caspase-8–dependent cleavage of gasdermin D and cell death (2018 · Science · 被引 1079)
• Design of amidobenzimidazole STING receptor agonists with systemic activity (2018 · Nature · 被引 901)
• RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer (2018 · Cancer Cell · 被引 254)
• A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection (2021 · Science Immunology · 被引 170)
• Respiratory Syncytial Virus Infection Promotes Necroptosis and HMGB1 Release by Airway Epithelial Cells (2020 · American Journal of Respiratory and Critical Care Medicine · 被引 132)
• Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer (2019 · ACS Medicinal Chemistry Letters · 被引 89)